kabutan

Astellas Pharma Inc.(4503) Summary

4503
TSE Prime
Astellas Pharma Inc.
1,487.0
JPY
+9.5
(+0.64%)
Jul 28, 1:10 pm JST
10.06
USD
Jul 28, 12:10 am EDT
Result
PTS
outside of trading hours
1,486.6
Jul 28, 1:09 pm JST
Summary Chart Historical News Financial Result
PER
20.4
PBR
1.76
Yield
5.25%
Margin Trading Ratio
30.74
Stock Price
Jul 28, 2025
Opening Jul 28, 9:00 am
1,479.0 JPY 10.00 USD
Previous Close Jul 25
1,477.5 JPY 10.05 USD
High Jul 28, 9:17 am
1,494.0 JPY 10.11 USD
Low Jul 28, 9:00 am
1,477.5 JPY 9.99 USD
Volume
2,925,300
Trading Value
4.35B JPY 0.03B USD
VWAP
1486.02 JPY 10.06 USD
Minimum Trading Value
148,700 JPY 1,006 USD
Market Cap
2.69T JPY 0.02T USD
Number of Trades
4,527
Liquidity & Number of Trades
As of Jul 28, 2025
Liquidity
High
1-Year Average
5,930
1-Year High Aug 6, 2024
25,178
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jul 18, 2025 901,100 3,670,500 4.07
Jul 11, 2025 713,100 4,043,800 5.67
Jul 4, 2025 708,200 4,130,600 5.83
Jun 27, 2025 694,500 4,014,900 5.78
Jun 20, 2025 726,200 4,450,500 6.13
Company Profile
Astellas Pharma Inc. is the second-largest pharmaceutical company in Japan, specializing in innovative drugs. The company has particular strengths in urology and transplantation, and is focusing on anticancer drugs.
Sector
Pharmaceuticals
Astellas Pharma Inc. was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The company's main business is the research and development, manufacturing, and sales of pharmaceuticals, with operations spanning globally. In research and development, Astellas focuses on cutting-edge fields such as regenerative medicine and gene therapy, primarily through its U.S. subsidiaries. The company has 11 production sites worldwide, including in Ireland, the Netherlands, and China. Its sales network covers approximately 70 countries where it conducts direct sales, including the United States, Germany, China, France, Spain, and South Korea. Astellas has established an integrated pharmaceutical business across its group, collaborating with regional affiliates to supply raw materials and products. The company operates in a single business segment - pharmaceuticals - leveraging its global R&D infrastructure and sales network for business expansion.